Influx Healthtech Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 29.1. ROE: 45.4%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q1 FY26 earnings • Updated Mar 21, 2026
What: Filing 10-12 ANDAs in FY26 with market share gains in US generics
Impact: +₹1954 Cr revenue
“Management confident of filing 10-12 ANDAs over the year with mid-teens growth in FY26E”
What: Gaining market share in US generics as competitors exit
Impact: +₹260 Cr revenue
“Market share gains in existing US products contributed to growth due to competitors exiting”
What: New chronic therapy product launches across Asia
Impact: +₹130 Cr revenue
“Asia sales grew 10% YoY to ₹304 cr driven by 10 new product launches”
Earnings deceleration risks from management commentary
Trigger: Continued investment in pipeline
Impact: -200 bps margin impact
Management view: Margin guidance revised to 26-27% range vs earlier 28-29% due to higher costs
Monitor: Quarterly OPM trend
Trigger: Slower-than-expected cost rationalization
Impact: -100 bps margin impact
Management view: Expect launch-related and employee expenses to normalise from FY27E
Monitor: Employee cost as % of revenue
Key quotes from recent conference calls
“Management also remains confident of filing 10–12 ANDAs over the year. — Management”
“Management has revised its margin guidance downward, now expecting FY26 margins to remain in the 26–27% range (vs. earlier 28–29%). — Management”
“Market share gains in existing US products contributed to growth, partly due to some competitors exiting the market. — Management”
“Backed by a strong pipeline and ramp-up of recent launches, we believe the company is well-positioned to sustain its growth momentum and deliver mid-teens growth in FY26E. — Management”
Forward-looking targets from management for FY26
Revenue Growth Target
15%
Implied PAT Growth
8%
OPM Guidance
26.5%
Key Milestones
• 10-12 ANDA filings
• Mid-teens revenue growth
• Margin stabilization at 26-27%
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 21, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Influx Healthtech Ltd's latest quarterly results (Sep 2025) show
Influx Healthtech Ltd's current PE ratio is 29.1x.
Influx Healthtech Ltd's price-to-book ratio is 5.7x.
Influx Healthtech Ltd's fundamental strength based on key financial ratios
Influx Healthtech Ltd has a debt-to-equity ratio of N/A.
Influx Healthtech Ltd's return ratios over recent years
Influx Healthtech Ltd's operating cash flow is positive (FY2025).
Influx Healthtech Ltd currently does not pay a significant dividend (yield 0.00%).
Influx Healthtech Ltd's shareholding pattern (Sep 2025)
Influx Healthtech Ltd's promoter holding has remained stable recently.
Influx Healthtech Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Influx Healthtech Ltd has 3 key growth catalysts identified from recent earnings analysis
Influx Healthtech Ltd has 2 key risks worth monitoring
In Q1 FY26, Influx Healthtech Ltd's management highlighted
Influx Healthtech Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why Influx Healthtech Ltd may be worth studying
Influx Healthtech Ltd investment thesis summary:
Influx Healthtech Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
